Blockchain Registration Transaction Record

Creative Biolabs Expands Retrovirus Antibody Portfolio

Creative Biolabs expands its antibody portfolio for HIV-1, HIV-2, and HTLV-1 research, offering new tools for virology, vaccine development, and diagnostic assays.

This expansion matters because human retroviruses like HIV-1, HIV-2, and HTLV-1 continue to pose significant global health challenges, and research into their structural and envelope proteins is essential for developing effective vaccines, diagnostics, and therapies. By providing well-characterized antibodies against key targets such as gp140, gp36, and gag p19, Creative Biolabs empowers scientists to better understand viral entry, immune evasion, and pathogenesis. These tools can accelerate the discovery of broadly neutralizing antibodies, improve assay development, and ultimately contribute to the fight against retroviral diseases that affect millions worldwide. As the scientific community strives for an HIV vaccine and better treatments for HTLV-1-associated diseases, access to reliable research reagents is a critical piece of the puzzle.